Organization announcement – No. 1 / 2021
- Net operating charges in 2020 are expected to be higher than the beforehand guided selection of DKK 950-1,000 million by roughly 5-10%.
Copenhagen, January 22, 2021 – with reference to the firm announcement dated 12 November 2020 (interim report for the interval 1 January 2020 to 30 September 2020), Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology organization focused on the discovery, progress and commercialization of modern peptide-based mostly medications, announces an update to the economic advice for 2020 (primarily based on preliminary and unaudited figures).
Zealand expects amplified typical functioning price steerage by somewhere around 5-10% (complete operating charges of DKK 1,050 million to 1,100 million).
Zealand will announce the specific and audited financial benefits, and expects to supply outlook for 2021, in the 2020 Once-a-year Report to be unveiled on 11 March 2021.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology corporation concentrated on the discovery, advancement and commercialization of revolutionary peptide-based mostly medications. A lot more than 10 drug candidates invented by Zealand have superior into clinical progress, of which two have achieved the market place. Zealand’s strong pipeline of investigational medications includes three candidates in late stage development, and one applicant remaining reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-a single basal-bolus insulin supply possibility for persons with diabetes. License collaborations with Boehringer Ingelheim and Alexion Prescribed drugs develop chance for far more people to most likely gain from Zealand-invented peptide therapeutics.
Zealand was launched in 1998 in Copenhagen, Denmark, and has presence all over the U.S. that includes crucial areas in New York, Boston, and Marlborough (MA). For more data about Zealand’s business and pursuits, please take a look at www.zealandpharma.com.
For further details, make sure you call:
Mads Kronborg
Head of Trader Relations & Conversation
Cellphone: +45 5060 3707
Email: mkronborg@zealandpharma.com
For U.S. Media
David Rosen
Argot Partners
Cell phone: 212-600-1902
Email: media@zealandpharma.com
- 1-2021 Zealand Pharma announces update to 2020 financial steerage